Clinical trial
An Open-label Phase 1/2/3 Study Consisting of a Phase 1/2 Safety and Dose-escalation and Phase 3 Dose-expansion Study to Evaluate Safety and Efficacy of a Single Intrathecal Administration of TSHA-102, an AAV9-Delivered Gene Therapy in Females With Rett Syndrome
NCT05606614 is registered in ClinicalTrials.gov with Taysha Gene Therapies, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label Phase 1/2/3 Study Consisting of a Phase 1/2 Safety and Dose-escalation and Phase 3 Dose-expansion Study to Evaluate Safety and Efficacy of a Single Intrathecal Administration of TSHA-102, an AAV9-Delivered Gene Therapy in Females With Rett Syndrome
- Lead sponsor
- Taysha Gene Therapies, Inc.
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- March 6, 2023
- Completion date
- June 30, 2031
- Enrollment
- 17 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.